Sign up to The Irish Times Archive (1859 - 2008)My Account »

Athlone-based pharmaceutical group Elan has today reported net income of $52.3 million for its fiscal third quarter compared to a loss of $83.5 million last year.

For the third quarter of 2009, Elan reported adjusted earnings before interest, tax, depreciation and amortisation (Ebitda) of $23.8 million, compared to a loss of $1.6 million in the same period a year earlier.